Google health info exec leaves company

Share this article:

Adam Bosworth, Google's executive in charge of leading the company's health information efforts, has left the company to pursue other interests.

"Adam is a great talent and was instrumental in starting Google Health,” Google spokesman Steve Langdon told MM&M in an e-mailed statement. “He is now on vacation and has decided to pursue other opportunities after that.”

Marissa Mayer, VP of search products & user experience, will take over Google's health team until a new leader is appointed, Langdon said.

“Google is moving forward with work on our health products," Langdon added.

Bosworth joined Google three years ago and had been thought to be working on a major new health service at the company. Google watchers have speculated the new, yet-to-be unveiled service could be centered on ideas ranging from health information search to ways to allow consumers to create their own personal medical records.

Prior to joining Google, Bosworth was a VP at business software provider BEA Systems. He previously held management positions at Microsoft where he worked with Web coding system Ajax, which has given rise to several Web 2.0 applications.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...